Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2020-04, Vol.22 (4), p.492-500
• Main Authors: Dejgaard, Thomas F., Schmidt, Signe, Frandsen, Christian S., Vistisen, Dorte, Madsbad, Sten, Andersen, Henrik U., Nørgaard, Kirsten
• Format: Article
• Language: English
• Subjects: Antidiabetics; Body weight; Clinical trials; Diabetes; Diabetes mellitus (insulin dependent); Drug therapy; GLP-1 receptor agonists; Glucagon; Hemoglobin; Hyperglycemia; Hypoglycemia; Insulin; Obesity; Overweight; Weight control
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.13911

Aim To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control. Materials and methods A 26‐week, randomized, double‐blind, placebo‐controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment. The primary endpoint was change in haemoglobin A1c (HbA1c). Secondary endpoints included change in insulin dose, CSII settings, glycaemic variability, body weight and patient‐reported outcome measures. Finally, adverse effects including hypoglycaemic events were registered. Results HbA1c was reduced by 5 mmol/mol (0.5%) from a baseline of 66 mmol/mol (8.2%) in patients treated with liraglutide compared with a non‐significant change of +2.3 mmol/mol (0.2%) from a baseline of 66 mmol/mol (8.1%) in patients treated with placebo (between‐group difference 7 mmol/mol [0.7%], P